Praluent (Alirocumab) Cost in North Carolina 2026

What Is the Cash Price for Praluent in North Carolina?

The manufacturer list price for Praluent is approximately $580 per month at North Carolina retail pharmacies in 2026, with minimal variation between chains. Without insurance or a savings program, patients pay close to that full amount out of pocket.

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells 1. By blocking PCSK9, the drug raises the number of functional LDL receptors and dramatically lowers circulating LDL-C. The ODYSSEY LONG TERM trial (N=2,341) demonstrated a mean LDL-C reduction of 61.9% from baseline at 24 weeks in patients receiving alirocumab 150 mg every two weeks versus placebo 2.

At retail, the $580 monthly figure reflects the wholesale acquisition cost (WAC). GoodRx and pharmacy discount programs can trim this modestly, to roughly $510, $540 at some NC locations, but these discounts are inconsistent and cannot be combined with insurance. Patients who lack commercial coverage and do not qualify for the manufacturer savings card face the steepest burden. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol identifies PCSK9 inhibitors as a second-line option after maximally tolerated statin therapy for patients with LDL-C persistently at or above 70 mg/dL in very high cardiovascular risk groups 3.

Does North Carolina Medicaid Cover Praluent?

North Carolina Medicaid does not cover Praluent for familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) as of 2026. Coverage exists only for a narrow T2D-linked dyslipidemia pathway, and even that requires documented statin intolerance plus prior authorization.

This coverage gap affects tens of thousands of NC Medicaid beneficiaries with high cardiovascular risk. The ODYSSEY OUTCOMES trial (N=18,924) published in the New England Journal of Medicine showed that alirocumab reduced major adverse cardiovascular events by 15% (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) in acute coronary syndrome patients versus placebo 4. That magnitude of benefit makes the coverage exclusion clinically significant for Medicaid enrollees who cannot afford the list price.

NC Medicaid's Drug Policy Unit periodically reviews the preferred drug list (PDL). Advocates and prescribers may submit clinical exception requests through the NC DHHS DUR Board process. A patient with heterozygous FH and LDL-C above 190 mg/dL despite maximally tolerated statin therapy represents the strongest exception case under current guidelines 5. Providers should document statin dose, duration, any intolerance, and baseline LDL-C in the exception request.

For patients in the 138% FPL Medicaid expansion tier, Regeneron's patient assistance program (see below) may partially fill the gap when the exception is denied.

Is Compounded Alirocumab Legal in North Carolina?

Compounded alirocumab from a licensed 503A compounding pharmacy is legal in North Carolina in 2026. Patients can obtain it through a valid prescription from a licensed NC provider.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound drug preparations for individual patients based on a valid prescription 6. North Carolina follows federal 503A rules under the oversight of the NC Board of Pharmacy. A 503A pharmacy may compound alirocumab because it is not on the FDA's "essentially a copy" list at this time, provided the compounded preparation is made for a specific patient with a specific prescription.

Key legal requirements for compounded alirocumab in NC include:

• A patient-specific prescription from a licensed NC prescriber.
• Preparation by a NC-licensed 503A pharmacy (not a 503B outsourcing facility, which has different rules).
• No wholesale distribution; the compound must be dispensed directly to the individual patient 6.
• The pharmacy must use USP-grade starting materials and follow current Good Compounding Practices.

The FDA has not placed alirocumab on the Demonstrably Difficult to Compound list as of 2026, meaning 503A pharmacies may legally prepare it 7. Clinically, the compounded product has not been evaluated in head-to-head trials against the branded biologic. Patients should discuss bioequivalence uncertainty with their prescriber before switching.

Cost for compounded alirocumab at NC 503A pharmacies varies by pharmacy but can reach as low as $0 per month for qualifying patients accessing subsidized compounding programs, compared with $580 per month for branded Praluent.

Which Insurance Plans Cover Praluent in North Carolina?

Most North Carolina commercial insurance plans cover Praluent under a specialty tier with prior authorization, step-therapy, and sometimes a quantity limit. Patient out-of-pocket costs after coverage typically range from $50 to $200 per month depending on the plan design.

Large NC employer plans governed by ERISA, ACA marketplace plans, and Medicare Part D each handle Praluent differently. The drug sits on specialty formulary tiers (Tier 4 or 5) for the majority of NC Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare plan designs. Standard prior authorization criteria across these payers generally mirror the ACC/AHA guideline thresholds 3:

1. LDL-C at or above 70 mg/dL in ASCVD patients despite maximally tolerated statin.
2. LDL-C at or above 100 mg/dL in heterozygous FH patients on optimized statin plus ezetimibe.
3. Documentation of at least one statin at the highest tolerated dose for at least 90 days.

Medicare Part D plans in NC vary substantially. CMS data show that fewer than 40% of Part D formularies place alirocumab on a preferred specialty tier, meaning most Medicare patients face the non-preferred specialty cost-sharing structure 8. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective 2025) reduces the financial exposure for Medicare beneficiaries on long-term Praluent therapy 9.

Step therapy is the single biggest PA obstacle. Nearly all NC commercial plans require documented failure or intolerance of at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) and often also require a trial of ezetimibe 10 mg before approving Praluent 10.

How the Regeneron / Sanofi Praluent Savings Card Works in North Carolina

Eligible commercially insured NC patients may pay as little as $0 per month for Praluent using the Regeneron/Sanofi copay savings card. The program caps the patient's out-of-pocket contribution regardless of insurance tier.

The savings card is available at PraluEntConnect.com and is processed at the pharmacy point of sale alongside insurance. The program covers the gap between what the insurer pays and what the patient owes, up to the program's maximum benefit per year. As of 2026, the card covers up to $250 per fill for commercially insured patients, effectively zeroing out most copay and coinsurance amounts.

Patients who are uninsured, enrolled in Medicare, Medicaid, or any other federal or state government health program are not eligible for the savings card under federal anti-kickback statute requirements 11. This restriction leaves a significant population of NC patients, particularly those on NC Medicaid or Medicare Part D, without access to the manufacturer's most generous discount.

For Medicare Part D patients, the Praluent Medicare patient assistance program (income-based) is separate from the commercial savings card. Patients with household income at or below 400% of the federal poverty level may qualify for free or reduced-cost drug through the Regeneron Patient Assistance Program 12. Prescribers may refer patients to NeedyMeds.org or RxAssist.org for application support.

North Carolina also participates in the Extra Help (Low Income Subsidy) program through CMS, which can substantially reduce Part D cost-sharing for alirocumab in qualifying Medicare enrollees 13.

Clinical Profile: Why Alirocumab Is Prescribed in North Carolina

Praluent is FDA-approved for two indications that are common in NC's patient population: (1) adults with established ASCVD to reduce CV events, and (2) adults with primary hyperlipidemia including heterozygous FH 1.

North Carolina has one of the higher rates of cardiovascular disease mortality in the southeastern United States. CDC data show NC's age-adjusted heart disease death rate at 167.2 per 100,000 population, above the national average of 161.5 14. That burden gives alirocumab outsized clinical relevance for NC providers treating high-risk lipid patients.

The ODYSSEY OUTCOMES trial remains the primary evidence base for alirocumab's cardiovascular benefit 4. Among patients with recent acute coronary syndrome randomized to alirocumab 75 to 150 mg every two weeks (titrated to LDL-C target), the absolute risk reduction in the primary composite endpoint (CHD death, nonfatal MI, ischemic stroke, unstable angina requiring hospitalization) was 1.6 percentage points over a median follow-up of 2.8 years. The number needed to treat was approximately 63 to prevent one primary event.

A secondary analysis of ODYSSEY OUTCOMES found that patients with baseline LDL-C at or above 100 mg/dL derived a larger absolute benefit, with a 24% relative risk reduction in all-cause mortality (HR 0.71 to 95% CI 0.56, 0.90) in that subgroup 4.

The 2022 ACC/AHA guideline states: "In patients with very high-risk ASCVD not at LDL-C goal despite maximally tolerated statin and ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, LOE A)" 3. That Class I designation is the guideline's strongest level of recommendation.

For patients with heterozygous FH, the Familial Hypercholesterolemia Foundation recommends cascade screening and aggressive LDL-C reduction as early as possible. FH affects roughly 1 in 250 individuals in the general population 15, meaning approximately 40,000 North Carolinians carry an FH-causing variant based on the state's population of roughly 10.7 million.

Telehealth Prescribing of Alirocumab in North Carolina

Alirocumab may be prescribed by a licensed NC provider via telehealth, and North Carolina's telehealth regulations do not restrict prescribing of non-controlled specialty medications through synchronous audio-video visits.

NC General Statute 90-18 and the NC Medical Board's 2020 telemedicine policy both allow a prescriber-patient relationship to be established via telemedicine when the standard of care for evaluation can be met 16. For alirocumab, establishing that relationship requires at minimum a review of lipid panel results (including LDL-C), documentation of prior statin therapy, and assessment of cardiovascular risk using a validated tool such as the ACC/AHA Pooled Cohort Equation 17.

HealthRX providers conducting telehealth visits in NC follow this workflow before prescribing alirocumab:

1. Collect lipid panel dated within 90 days (LDL-C, total cholesterol, HDL-C, triglycerides).
2. Review prior statin therapy: drug name, dose, duration, and any adverse effects.
3. Calculate 10-year ASCVD risk score. Document FH diagnosis if applicable using Simon Broome or Dutch Lipid Clinic Network criteria 18.
4. Confirm insurance status and initiate PA if required.
5. Submit prescription electronically to pharmacy of patient's choice; refer to savings card if commercially insured.

Alirocumab is self-administered via subcutaneous injection. Most patients can learn the injection technique through a brief video demonstration, making remote onboarding practical. The autoinjector pen design requires no reconstitution and is stored in a standard refrigerator at 36, 46°F 1.

Dosing, Administration, and Monitoring

Standard starting doses are 75 mg every two weeks or 300 mg once monthly via subcutaneous injection. If LDL-C reduction is insufficient at 75 mg every two weeks after 4 to 8 weeks, the dose may be titrated to 150 mg every two weeks 1.

LDL-C should be measured 4 to 8 weeks after initiation or dose change to confirm adequate response. A repeat fasting lipid panel at 12 weeks is consistent with ACC/AHA monitoring recommendations 3. No dose adjustment is required for mild-to-moderate renal impairment. Hepatic impairment data for severe disease (Child-Pugh C) are limited; the FDA label recommends caution in that setting 1.

The most common adverse effects in clinical trials were nasopharyngitis (11.3%), injection-site reactions (7.2%), and influenza (5.7%) with alirocumab versus placebo in ODYSSEY LONG TERM 2. Neurocognitive events were reported more frequently in the alirocumab arm of early trials, but a dedicated 52-week neurocognitive safety study (EBBINGHAUS, N=1,204) found no significant difference in cognitive function between alirocumab and placebo groups 19.

Practical Cost-Reduction Roadmap for NC Patients

Getting Praluent's effective monthly cost below $100 in North Carolina requires a specific sequence of steps, not simply visiting a pharmacy.

Step 1. Obtain a fasting lipid panel and confirm LDL-C meets guideline thresholds. Without documentation, no PA will be approved.

Step 2. Have the prescriber submit a PA through the insurer's portal, attaching the lipid panel, statin trial records, and ezetimibe trial records if required. Most NC commercial plans decide within 3, 5 business days 20.

Step 3. If commercially insured and PA is approved, apply the Regeneron/Sanofi savings card at the pharmacy. Expected out-of-pocket: $0, $50 per fill.

Step 4. If PA is denied, request a peer-to-peer review between the prescribing physician and the plan's medical director within the insurer's appeal window (typically 30 days for standard appeals).

Step 5. If coverage is denied on appeal and the patient remains uninsured or Medicaid-enrolled, request a referral to a licensed NC 503A compounding pharmacy for compounded alirocumab. Confirm the pharmacy's NC Board of Pharmacy license before dispensing 21.

Step 6. For patients with income at or below 400% FPL without any drug coverage, submit a Regeneron Patient Assistance Program application 12.

Injection-site reactions with compounded alirocumab should be reported to the prescriber and to MedWatch, the FDA's voluntary adverse event reporting system 22.

NC Provider Considerations: PA Language That Gets Approved

Prior authorizations for alirocumab in NC are denied most often because of incomplete documentation of prior statin therapy. Three documentation elements correlate with approval rates in commercial plan appeals:

First, include the exact statin dose and duration. "The patient received atorvastatin 80 mg daily for 16 weeks" is more persuasive than "the patient tried statins." Second, if statin intolerance is the basis for the PA, list the specific symptom (myalgia with CPK elevation, hepatotoxicity, etc.) and the date it was documented 23. Third, cite the guideline directly. The 2022 ACC/AHA Class I, LOE A recommendation for PCSK9 inhibitors in very-high-risk patients is difficult for a plan medical director to override on clinical grounds 3.

The Familial Hypercholesterolemia Foundation's FH patient registry (CASCADE FH) includes NC sites and can provide supporting documentation for FH diagnosis in complex cases 24.

A 2020 analysis in JAMA Cardiology found that peer-to-peer reviews for PCSK9 inhibitors resulted in PA approval in 56% of initially denied cases when the requesting physician was board-certified in cardiology or endocrinology 25. Engaging a specialist for the peer-to-peer call meaningfully improves success rates for NC patients.